User Fee Workload Decline Leads To Staff Decreases In Regulatory Affairs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Regulatory Affairs will reduce its Prescription Drug User Fee Act II-funded staff by 40 full-time equivalents for each of the remaining two years of the act's authorization period. The plan calls for 10 fewer FTEs in fiscal 1999, and for 40 fewer FTEs in each subsequent year through 2002.